NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy
Portfolio Pulse from
NeuroNOS, a subsidiary of Beyond Air, secured $2 million in initial equity financing to advance a novel small-molecule drug for Autism Spectrum Disorder (ASD). The therapy aims to regulate nitric oxide levels in the brain, with potential to improve behavioral and cognitive functions in children with autism. First-in-human studies are anticipated to begin in 2026, focusing on subcutaneous and potential oral formulations.
March 24, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Beyond Air's subsidiary NeuroNOS has secured initial funding to develop an innovative autism therapy, potentially expanding the parent company's neurological research portfolio.
The funding and research progress of NeuroNOS could positively impact Beyond Air's market perception, potentially driving investor interest in the parent company's broader neurological research capabilities.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70